Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …

Natural bicyclic sesquiterpenes, β‐caryophyllene (BCP) and β‐caryophyllene oxide (BCPO),
are present in a large number of plants worldwide. Both BCP and BCPO (BCP (O)) possess …

Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

Cognitive impairment is commonly associated with the pain experience. This impairment
represents a major obstacle to daily activities and rehabilitation, especially in the chronic …

Background Medicinal cannabis registries typically report pain as the most common reason
for use. It would be clinically useful to identify patterns of cannabis treatment in migraine and …

Chronic pain can be recurrent or constant pain that lasts for longer than 3 months and can
result in disability, suffering, and a physical disturbance. Related to the complex nature of …

Background The use of cannabis, or marijuana, for medicinal purposes is deeply rooted
though history, dating back to ancient times. It once held a prominent position in the history …

A wealth of research over the past 2 decades has expanded our understanding of the impact
of early‐life adversity on physiological function and, consequently, health and wellbeing in …

Glia have emerged as key contributors to pathological and chronic pain mechanisms. On
activation, both astrocytes and microglia respond to and release a number of signalling …

Objective: This review consists of three parts, representing three different possibilities of
interactions between cannabinoid receptor ligands of both exogenous and endogenous …